scholarly journals OC-045 Socioeconomic inequality in head and neck cancer survival- a population-based study from DAHANCA

2019 ◽  
Vol 132 ◽  
pp. 23-24
Author(s):  
M.H. Olsen ◽  
P. Lassen ◽  
C. Rotbøl ◽  
T.K. Kjær ◽  
E.A.W. Andersen ◽  
...  
Author(s):  
Ahmed Bedir ◽  
Semaw Ferede Abera ◽  
Ljupcho Efremov ◽  
Lamiaa Hassan ◽  
Dirk Vordermark ◽  
...  

Abstract Purpose Despite recent improvements in cancer treatment in Germany, a marked difference in cancer survival based on socioeconomic factors persists. We aim to quantify the effect of socioeconomic inequality on head and neck cancer (HNC) survival. Methods Information on 20,821 HNC patients diagnosed in 2009–2013 was routinely collected by German population-based cancer registries. Socioeconomic inequality was defined by the German Index of Socioeconomic Deprivation. The Cox proportional regression and relative survival analysis measured the survival disparity according to level of socioeconomic deprivation with respective confidence intervals (CI). A causal mediation analysis was conducted to quantify the effect of socioeconomic deprivation mediated through medical care, stage at diagnosis, and treatment on HNC survival. Results The most socioeconomically deprived patients were found to have the highest hazard of dying when compared to the most affluent (Hazard Ratio: 1.25, 95% CI 1.17–1.34). The most deprived patients also had the worst 5-year age-adjusted relative survival (50.8%, 95% CI 48.5–53.0). Our mediation analysis showed that most of the effect of deprivation on survival was mediated through differential stage at diagnosis during the first 6 months after HNC diagnosis. As follow-up time increased, medical care, stage at diagnosis, and treatment played no role in mediating the effect of deprivation on survival. Conclusion This study confirms the survival disparity between affluent and deprived HNC patients in Germany. Considering data limitations, our results suggest that, within six months after HNC diagnosis, the elimination of differences in stage at diagnosis could reduce survival inequalities.


PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0229266 ◽  
Author(s):  
Christoph Evers ◽  
Christian Ostheimer ◽  
Frank Sieker ◽  
Dirk Vordermark ◽  
Daniel Medenwald

Oral Oncology ◽  
2020 ◽  
Vol 102 ◽  
pp. 104561 ◽  
Author(s):  
Sabine Stordeur ◽  
Viki Schillemans ◽  
Isabelle Savoye ◽  
Katrijn Vanschoenbeek ◽  
Roos Leroy ◽  
...  

2016 ◽  
Vol 25 (5) ◽  
pp. 1529-1536 ◽  
Author(s):  
Tzu-Lung Kuo ◽  
Ching-Heng Lin ◽  
Rong-San Jiang ◽  
Ting-Ting Yen ◽  
Chen-Chi Wang ◽  
...  

2013 ◽  
Vol 52 (2) ◽  
pp. 430-439 ◽  
Author(s):  
Trille Kjær ◽  
Charlotte Rotbøl Bøje ◽  
Maja Halgren Olsen ◽  
Jens Overgaard ◽  
Jørgen Johansen ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0174574 ◽  
Author(s):  
Chung-I Huang ◽  
Li-Ching Lin ◽  
Hung-Cheng Tien ◽  
Jenny Que ◽  
Wei Chen Ting ◽  
...  

2021 ◽  
pp. JCO.20.01845
Author(s):  
Christopher W. Noel ◽  
Rinku Sutradhar ◽  
Haoyu Zhao ◽  
Victoria Delibasic ◽  
David Forner ◽  
...  

PURPOSE: To determine the association between patient-reported symptom burden and subsequent emergency department use and unplanned hospitalization (ED/Hosp) in a head and neck cancer (HNC) patient population. METHODS: This was a population-based study of patients diagnosed with HNC who had completed at least one outpatient Edmonton Symptom Assessment System (ESAS) assessment between January 2007 and March 2018 in Ontario, Canada. Logistic regression models were used to determine the relationship between outpatient ESAS scores and subsequent 14-day ED/Hosp use. A generalized estimating equation approach with an exchangeable correlation structure was incorporated to account for patient-level clustering RESULTS: There were 11,761 patients identified, completing a total of 73,282 ESAS assessments and experiencing 5,203 ED/Hosp events. Six of the nine ESAS symptom scores were positively associated with ED/Hosp use, with pain, appetite, shortness of breath, and tiredness demonstrating the strongest associations. A global ESAS score was calculated by selecting the highest individual symptom score (h-ESAS). Among patients reporting a maximum h-ESAS score of 10, 15.1% had an ED/Hosp event within 14 days compared with 1.5% for those with the lowest possible score of zero. In adjusted analysis, the odds of ED/Hosp use increased with h-ESAS (1.23 per one-unit increase [95% CI, 1.22 to 1.25]). When treated as a categorical variable, patients with the maximum h-ESAS score of 10 had 9.23 (95% CI, 7.22 to 11.33) higher odds of ED/Hosp use, relative to the minimum score of zero. CONCLUSION: ESAS scores are strongly associated with subsequent ED/Hosp events in patients with HNC. Clinician education around how ESAS data might inform patient care may enhance symptom detection and management.


Sign in / Sign up

Export Citation Format

Share Document